Rare Disease
Batten Disease
3
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Batten Disease is an early-stage landscape with 3 programs across 3 companies. The most active players are Roche, Pfizer, BioMarin Pharmaceutical.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Protein / enzyme150%
Modality classified for 67% of 3 pipeline programs.
Analysis
Trial Status
2
clinical trials
Recruiting1 · 50%
Active, not recruiting1 · 50%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)